-
EP3186257
European procedure
Extract from the Register of European Patents
EP About this file: EP3186257
| EP3186257 - NOVEL CHROMONE OXIME DERIVATIVE AND ITS USE AS ALLOSTERIC MODULATOR OF METABOTROPIC GLUTAMATE RECEPTORS [Right-click to bookmark this link] | Status | No opposition filed within time limit Status updated on 13.12.2019 Database last updated on 18.11.2024 | |
| Former | The patent has been granted Status updated on 04.01.2019 | ||
| Former | Grant of patent is intended Status updated on 14.08.2018 | ||
| Former | Request for examination was made Status updated on 02.06.2017 | ||
| Former | The international publication has been made Status updated on 27.03.2017 | Most recent event Tooltip | 27.09.2024 | Change - lapse in a contracting state | published on 30.10.2024 [2024/44] | Applicant(s) | For all designated states Prexton Therapeutics SA 14 Chemin des Aulx 1228 Plan les Ouates, Geneva / CH | [2019/06] |
| Former [2017/27] | For all designated states Prexton Therapeutics SA 14 Chemin des Aulx 1228 Plan les Ouates, Geneva / CH | Inventor(s) | 01 /
CHARVIN, Delphine 487 rue des Vertes Campagnes F-01170 Gex / FR | 02 /
MANTEAU, Baptiste 13 rue de la Liberté F-67380 Lingolsheim / FR | 03 /
POMEL, Vincent 228 chemin du Bois des Pesses F-74570 Groisy / FR | 04 /
CONQUET, François 86 route des Pitons 74160 Beaumont / FR | [2017/27] | Representative(s) | H. Lundbeck A/S Ottiliavej 9 2500 Valby / DK | [2019/06] |
| Former [2017/27] | Vossius & Partner Patentanwälte Rechtsanwälte mbB Siebertstrasse 3 81675 München / DE | Application number, filing date | 15770814.0 | 27.08.2015 | [2017/27] | WO2015EP69601 | Priority number, date | EP20140182468 | 27.08.2014 Original published format: EP 14182468 | [2017/27] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2016030444 | Date: | 03.03.2016 | Language: | EN | [2016/09] | Type: | A1 Application with search report | No.: | EP3186257 | Date: | 05.07.2017 | Language: | EN | The application published by WIPO in one of the EPO official languages on 03.03.2016 takes the place of the publication of the European patent application. | [2017/27] | Type: | B1 Patent specification | No.: | EP3186257 | Date: | 06.02.2019 | Language: | EN | [2019/06] | Search report(s) | International search report - published on: | EP | 03.03.2016 | Classification | IPC: | C07D495/04, A61K31/407, A61P25/16 | [2017/27] | CPC: |
C07D495/04 (EP,IL,KR,RU,US);
A61K31/353 (KR);
A61K31/407 (RU);
A61K31/4365 (KR);
A61K31/5377 (EP,KR,US);
A61K9/0053 (KR);
A61P25/00 (EP);
A61P25/04 (EP);
A61P25/08 (EP);
A61P25/14 (EP);
A61P25/16 (EP,RU);
A61P25/18 (EP);
A61P25/22 (EP);
A61P25/24 (EP);
A61P25/28 (EP);
A61P25/32 (EP);
A61P29/00 (EP);
A61P29/02 (EP);
A61P3/00 (EP);
A61P3/02 (EP);
A61P3/08 (EP);
A61P3/10 (EP);
A61P31/18 (EP);
A61P35/00 (EP);
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2017/27] | Extension states | BA | 31.03.2017 | ME | 31.03.2017 | Validation states | MA | 31.03.2017 | Title | German: | NEUARTIGE CHROMON-OXIMDERIVATE UND DEREN VERWENDUNG ALS ALLOSTERISCHE MODULATOREN VON METABOTROPEN GLUTAMATREZEPTOREN | [2018/34] | English: | NOVEL CHROMONE OXIME DERIVATIVE AND ITS USE AS ALLOSTERIC MODULATOR OF METABOTROPIC GLUTAMATE RECEPTORS | [2017/27] | French: | NOUVEAU DÉRIVÉ D'OXIME DE CHROMONE ET SON UTILISATION COMME MODULATEUR ALLOSTÉRIQUE DE RÉCEPTEURS MÉTABOTROPIQUES DU GLUTAMATE | [2018/34] |
| Former [2017/27] | NEUE CHROMON-OXIMDERIVATE UND IHRE VERWENDUNG ALS ALLOSTERISCHE MODULATOREN VON METABOTROPEN GLUTAMATREZEPTOREN | ||
| Former [2017/27] | NOUVEAU DÉRIVÉ D'OXIME DE CHROMONE ET SON UTILISATION COMME MODULATEUR ALLOSTÉRIQUE DE RÉCEPTEURS MÉTABOTROPES AU GLUTAMATE | Entry into regional phase | 27.03.2017 | National basic fee paid | 27.03.2017 | Designation fee(s) paid | 27.03.2017 | Examination fee paid | Examination procedure | 27.03.2017 | Amendment by applicant (claims and/or description) | 27.03.2017 | Examination requested [2017/27] | 27.03.2017 | Date on which the examining division has become responsible | 15.08.2018 | Communication of intention to grant the patent | 18.12.2018 | Fee for grant paid | 18.12.2018 | Fee for publishing/printing paid | 18.12.2018 | Receipt of the translation of the claim(s) | Divisional application(s) | EP19151429.8 / EP3502115 | EP19217991.9 / EP3696183 | Opposition(s) | 07.11.2019 | No opposition filed within time limit [2020/03] | Fees paid | Renewal fee | 23.08.2017 | Renewal fee patent year 03 | 31.08.2018 | Renewal fee patent year 04 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | |||
| Former [2022/31] | AL | 06.02.2019 | Cited in | International search | [AD]WO2011051478 (DOMAIN THERAPEUTICS [FR], et al) | by applicant | EP0787723 | WO2004092154 | WO2009010454 | WO2009010455 | WO2011051478 |